Efficacy of Splenectomy for Hematologic Malignancies: A Retrospective Cohort Study.
Splenectomy for hematologic malignancies is associated with a 49% 30-day complication rate.
Efficacy of Splenectomy for Hematologic Malignancies: A Retrospective Cohort Study.
With the advent of new therapies for hematologic malignancies, the diagnostic and therapeutic indications for splenectomy have changed.
This study aimed to define the evolving indications for splenectomy and benchmark clinical outcomes in patients with hematologic malignancies.
Were grouped by indication as lymphoid or myeloid; patients with benign conditions constituted a small descriptive subgroup.
Indications included bridge-to-transplant (35.4%), transfusion dependence (24.0%), symptomatic cytopenia (22.8%), and splenic malignancy (17.7%).
While myeloid patients had a higher proportion of patients experiencing any complication compared to lymphoid patients (65.5% vs 46.4%) (P=0.482).
Success rates were 91.7% for bridge-to-transplant but lower for achieving transfusion independence in cytopenia (38.5% lymphoid patients, 40% post-transplant myeloid patients, and 40% immune thrombocytopenic purpura patients).
Our results benchmark postoperative outcomes of splenectomy in a contemporary cohort with hematological malignancies. The success of splenectomy varies according to indication.
Appropriate splenectomy produces favorable outcomes across a broad range of hematologic malignancies, including improved transfusion independence and successful bridging to definitive therapies.